Aurobindo Pharma Ltd

Aurobindo Pharma Ltd

₹ 1,264 0.76%
03 Dec - close price
About

Aurobindo Pharma is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services.(Source : 202003 Annual Report Page No:159)

Key Points

Leading Pharmaceutical company [1]
Aurobindo Pharma is India’s second-largest pharma company & Largest generics company in the US (by Rx dispensed). It is also the largest generic company in the US and is amongst the top 10 generic companies in seven out of 11 countries in Europe.[2]The Company is among the top 5 listed pharmaceutical companies in India by FY22 revenues [3]

  • Market Cap 74,051 Cr.
  • Current Price 1,264
  • High / Low 1,593 / 958
  • Stock P/E 35.8
  • Book Value 335
  • Dividend Yield 0.36 %
  • ROCE 11.5 %
  • ROE 10.3 %
  • Face Value 1.00

Pros

  • Company has been maintaining a healthy dividend payout of 28.5%

Cons

  • Stock is trading at 3.77 times its book value
  • The company has delivered a poor sales growth of -2.78% over past five years.
  • Company has a low return on equity of 8.88% over last 3 years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024
2,883 2,623 2,887 1,742 1,948 2,361 2,406 2,391 2,669 2,692 2,894 2,460 2,825
2,543 2,407 2,380 1,529 1,680 1,917 1,830 1,968 2,124 2,210 2,119 1,961 2,104
Operating Profit 340 216 507 213 268 444 576 422 545 482 775 499 721
OPM % 12% 8% 18% 12% 14% 19% 24% 18% 20% 18% 27% 20% 26%
82 131 339 38 36 54 326 113 103 331 123 65 123
Interest 3 4 5 6 12 25 32 32 37 61 53 51 52
Depreciation 98 101 101 56 61 60 67 60 66 64 65 67 68
Profit before tax 320 242 740 189 231 413 804 444 546 687 780 446 724
Tax % 38% 1% -8% 35% 29% 28% 20% 24% 24% 9% 26% 26% 26%
198 240 802 122 165 299 645 336 416 624 579 329 538
EPS in Rs 3.37 4.09 13.69 2.08 2.81 5.10 11.01 5.74 7.10 10.65 9.88 5.62 9.17
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 TTM
5,424 7,108 8,069 9,158 9,607 10,270 12,258 13,371 15,824 11,287 8,457 10,646 10,871
4,462 5,187 5,816 6,705 7,215 7,600 9,838 10,670 11,704 9,783 6,952 8,422 8,394
Operating Profit 961 1,922 2,253 2,453 2,392 2,670 2,420 2,700 4,120 1,504 1,505 2,224 2,476
OPM % 18% 27% 28% 27% 25% 26% 20% 20% 26% 13% 18% 21% 23%
23 73 65 187 118 81 189 386 590 565 429 670 642
Interest 250 289 132 229 45 53 231 243 29 17 75 183 217
Depreciation 171 186 245 263 286 355 413 473 488 415 243 255 264
Profit before tax 563 1,519 1,940 2,148 2,179 2,343 1,965 2,370 4,193 1,637 1,616 2,457 2,637
Tax % 12% 23% 22% 24% 22% 23% 22% 21% 26% 11% 24% 20%
496 1,172 1,516 1,627 1,707 1,813 1,530 1,877 3,113 1,455 1,227 1,954 2,069
EPS in Rs 8.52 20.11 25.96 27.80 29.13 30.94 26.11 32.03 53.13 24.83 20.94 33.35 35.32
Dividend Payout % 9% 7% 9% 9% 9% 8% 10% 9% 8% 36% 36% 13%
Compounded Sales Growth
10 Years: 4%
5 Years: -3%
3 Years: -12%
TTM: 11%
Compounded Profit Growth
10 Years: 5%
5 Years: 5%
3 Years: -14%
TTM: 28%
Stock Price CAGR
10 Years: 8%
5 Years: 23%
3 Years: 23%
1 Year: 21%
Return on Equity
10 Years: 15%
5 Years: 12%
3 Years: 9%
Last Year: 10%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Sep 2024
Equity Capital 29 29 29 59 59 59 59 59 59 59 59 59 58
Reserves 2,910 3,983 5,330 6,807 8,378 9,924 11,292 12,994 15,866 17,059 17,975 19,664 19,598
2,782 2,925 3,285 4,165 3,054 3,719 4,520 3,741 4,042 1,895 4,203 2,861 4,266
1,103 1,638 1,582 1,534 1,533 2,092 2,270 2,770 3,222 2,589 2,822 2,570 2,740
Total Liabilities 6,825 8,576 10,226 12,566 13,023 15,794 18,141 19,564 23,189 21,601 25,059 25,154 26,663
2,012 1,938 2,190 2,568 3,212 3,393 4,150 4,418 4,472 3,586 3,688 2,419 2,406
CWIP 166 204 227 742 907 1,144 789 815 735 225 239 133 115
Investments 708 873 1,013 1,183 1,682 1,968 2,339 2,527 5,010 6,584 8,105 13,393 14,204
3,938 5,561 6,796 8,072 7,222 9,289 10,863 11,804 12,972 11,206 13,027 9,209 9,938
Total Assets 6,825 8,576 10,226 12,566 13,023 15,794 18,141 19,564 23,189 21,601 25,059 25,154 26,663

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
625 328 590 1,185 2,457 922 530 2,201 2,995 3,727 1,816 1,715
-295 -401 -624 -1,390 -1,542 -991 -1,301 -948 -2,650 -1,615 -3,230 -152
-229 -31 35 515 -1,329 440 599 -1,255 -28 -2,448 1,719 -1,837
Net Cash Flow 101 -105 1 310 -414 371 -171 -1 316 -335 306 -274

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 116 153 168 175 143 159 156 158 137 128 197 129
Inventory Days 174 179 207 207 191 273 235 242 244 210 335 148
Days Payable 109 130 111 109 96 130 109 107 104 130 179 112
Cash Conversion Cycle 181 202 264 273 239 301 282 293 277 208 353 166
Working Capital Days 167 182 208 220 197 236 242 234 208 241 305 162
ROCE % 15% 29% 27% 24% 20% 19% 15% 16% 23% 9% 8% 12%

Shareholding Pattern

Numbers in percentages

Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024
51.83% 51.83% 51.83% 51.84% 51.84% 51.84% 51.84% 51.84% 51.84% 51.84% 51.80% 51.82%
21.37% 20.83% 20.71% 21.41% 22.31% 23.03% 24.12% 22.45% 20.72% 18.01% 16.73% 16.59%
16.49% 17.47% 17.30% 16.56% 14.90% 15.09% 15.73% 18.29% 20.60% 23.28% 24.77% 25.14%
10.31% 9.86% 10.15% 10.20% 10.96% 10.06% 8.31% 7.43% 6.85% 6.87% 6.69% 6.45%
No. of Shareholders 3,41,5683,38,6393,59,6843,58,4593,69,8283,43,6172,93,2142,59,6382,41,9442,44,5752,38,6222,48,488

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Concalls